bioRxiv · 10.1101/808741
Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria
Abstract
Emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global health, necessitating the development of innovative antimicrobials. We established a series of CRISPR-Cas13a-based antibacterial nucleocapsid, termed CapsidCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus through promiscuous RNA cleavage after recognizing corresponding antimicrobial resistance genes. CapsidCas13a constructs were generated by packaging CRISPR-Cas13a into a bacteriophage capsid to target antimicrobial resistance genes. Contrary to Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are located on a plasmid, the CapsidCas13a(s) exhibited strong bacterial killing activities upon recognizing target genes regardless of their location. The antimicrobials treatment efficacy was confirmed using a Galleria mellonella larvae model. Further, we demonstrated that the CapsidCas13a(s) can assist in bacterial gene detection without employing nucleic acid amplification and optical devices.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kiga, K., Tan, X.-E., Ibarra-Chavez, R., Watanabe, S., Aiba, Y., Sato, Y., Li, F.-Y., Sasahara, T., Cui, B., Kawauchi, M., Boonsiri, T., Thitiananpakorn, K., Taki, Y., Azam, A. H., Suzuki, M., Penades, J. R., Cui, L.. 2019-10-17. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. https://doi.org/10.1101/808741
Cite the original work for its findings. Save a collection to share your selection of sources.